Axinn Patent Attorneys Discuss Insulins Under the BPCIA vs Hatch-Waxman
July 21, 2020
The Center for Biosimilars
On July 21, Axinn partner Ted Mathias participated in a video interview with The Center for Biosimilars. They discussed the differences in how insulins will be regulated under the Biologics Price Competition and Innovation Act (BPCIA) versus the Hatch-Waxman Act and the new challenges follow-on manufacturers will face.
Click here to access the interview.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
National Bar Association 100th Annual Convention and Exhibits
Sponsorship
Antitrust
Keeping Pace: Updates in Cartel Enforcement
Webinar
Antitrust
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
Navigating the Hart-Scott-Rodino Act in 2025
Webinar
Antitrust
AHLA Annual Meeting 2025
Speaking Engagement
Antitrust
State by State, Pre-Merger Notifications Expand
Axinn Viewpoints
Antitrust
FTC claims diverging market from EU in Mars/Kellanova clearance
Media Mentions
Keeping an Eye on the Ball: America First Antitrust Weighs in on the “Uniquely American System of Scholar Athletics”
Axinn Viewpoints
Antitrust
Wait, We Have To Tell Who? What You Need To Know About State Premerger Notifications
Podcast
MBK | MSK Fellowship Summit 2025
Sponsorship
Antitrust